RE:RE:RE:RE:"The reality is the boats are shaking" Areas such as
rare diseases, oncology, and immunology are particularly appealing, with investments in drugs nearing regulatory approval offering a more expedited and certain path to market. McKinsey reports an increasing percentage of revenue derived from externally sourced pharmaceutical innovation, emphasizing the significance of such deals.
Looking ahead, it is anticipated that the number of M&A deals involving small and medium-sized companies will accelerate over the next few quarters.
https://www.echemi.com/cms/1601111.html